Targeted therapy

Phase 2Small molecule

FFudan University

Targeted therapy is one of 274 small molecule programs targeting Toxicity. It is currently in Phase 2.

Indications

Total Trials

Active Trials

273

Competitors

Pipeline

Status by Indication[3][1]

Indication

ToxicityActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Colorectal CancerRecruiting

Pancreatic CancerNot yet recruiting

Prostate CancerRecruiting

Hepatocellular CarcinomaActive, not recruiting

CancerCompleted

HCC - Hepatocellular CarcinomaNot yet recruiting

First-LineNot yet recruiting

ToxicityPreclinical

Active, not recruiting

Non-Small Cell Lung CancerPreclinical

Active, not recruiting

Colorectal CancerPhase 2

Recruiting

Pancreatic CancerPhase 2

Not yet recruiting

Prostate CancerPhase 2

Recruiting

Hepatocellular CarcinomaPreclinical

Active, not recruiting

CancerPreclinical

Completed

HCC - Hepatocellular CarcinomaPhase 2

Not yet recruiting

First-LinePhase 2

Not yet recruiting

Competition

Competitive Landscape

414 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Yervoy

Bristol-Myers Squibb

Phase 3

32 2

Tuoyi

CCoherus Oncology, Inc.

Phase 3

9 3

Pyrotinib

HHengrui Therapeutics, Inc.

Phase 3

4 4

SHR-A1811

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3

3 5

Targeted therapy

FFudan University

Phase 2

1 6

Remeron

OOrganon and Co

Preclinical

1 7

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—8

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—9

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatment

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

Prostate Cancer

NCT06249750

Q3 2027

Phase 2Recruiting

Colorectal Cancer

NCT06521866

Q4 2028

Phase 2Not yet recruiting

First-Line

NCT06665087

Phase 2Not yet recruiting

Pancreatic Cancer

NCT07333287

Q2 2030

Phase 2Recruiting

Hepatocellular Carcinoma (HCC)

NCT07639138

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

Genetic Sequencing-Informed Targeted Therapy in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer

Terminated·FFox Chase Cancer Center·N/A·NCT02132884·1 enrolled

First-line1 trial

CGA Guided Ultrafractionated RT and First-line Systemic Treatment in Elderly or Frail Patients with MCRC

Not yet recruiting·FFudan University·Phase 2·NCT06665087·110 enrolled

Hepatocellular Carcinoma1 trial

TACE-HAIC Combined With TKIs and Immunotherapy Versus TACE Alone for Hepatocellular Carcinoma With PVTT

Completed·YYunfei Yuan··NCT05535998·743 enrolled

Colorectal Cancer1 trial

Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer

Recruiting·FFudan University·Phase 2·NCT06521866·208 enrolled

Prostate Cancer1 trial

Clinical Application of Near-infrared Whole Body Heat Shock Multimodal Technique in Treatment of Castration-resistant Prostate Cancer

Recruiting·PPengyuan Liu·Phase 2·NCT06249750·60 enrolled

6 more indications

Cancer1 trial

Next Generation Sequence Target-Directed Therapy in Treating Patients With Cancer

Completed·FFox Chase Cancer Center·N/A·NCT02132845·30 enrolled

Advanced Refractory Solid Tumors1 trial

a Prospective Registration Study for Patients With Advanced Refractory Solid Tumors

Unknown status·TThe University of Hong Kong-Shenzhen Hospital··NCT05177666·120 enrolled

Toxicity1 trial

A Single-cell Approach to Identify Biomarkers of Pulmonary Toxicity for Immune Checkpoint Blockade

Recruiting·UUniversitaire Ziekenhuizen KU Leuven··NCT04807127·60 enrolled

Pancreatic Cancer1 trial

A Multicenter Single-arm Prospective Clinical Study on First-line Treatment of Pancreatic Cancer Liver Metastases With Arterial Infusion Chemotherapy and Embolization Combined With Dual Immune Checkpoint Inhibitors.

Not yet recruiting·SShandong Provincial Hospital·Phase 2·NCT07333287·38 enrolled

Hepatocellular Carcinoma (HCC)1 trial

Safety and Efficacy of Lenalidomide Combined With Targeted Therapy and Immunotherapy in Patients With Advanced Hepatocellular Carcinoma Resistant to Multiple Prior Lines of Treatment: A Single-Center, Single-Arm, Prospective Exploratory Study

Recruiting·SShunda Du·Phase 2·NCT07639138·32 enrolled

HCC - Hepatocellular Carcinoma1 trial

Shuganhuazhuo Formula (Chinese Herbal Medicine) in the Combined Treatment of Advanced Hepatocellular Carcinoma With Damp-Heat and Blood Stasis Syndrome: An Open-Label Randomized Controlled Trial

Not yet recruiting·XXiang-Qian·Phase 2·NCT07691645·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for Targeted therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Targeted therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Targeted therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fudan University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: FFudan University

Targeted therapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q3 2027

Q4 2028

Q2 2030

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

First-line1 trial

Hepatocellular Carcinoma1 trial

Colorectal Cancer1 trial

Prostate Cancer1 trial

Cancer1 trial

Advanced Refractory Solid Tumors1 trial

Toxicity1 trial

Pancreatic Cancer1 trial

Hepatocellular Carcinoma (HCC)1 trial

HCC - Hepatocellular Carcinoma1 trial

References

Drug Info

Quick Facts

Related News